We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Exact Sciences Corp showcases robust revenue growth amidst operational challenges. Innovative cancer screening and diagnostic tests position the company at the forefront of the healthcare industry.

TD Cowen analyst Dan Brennan lowered the firm’s price target on Exact Sciences (EXAS) to $82 from $90 and keeps a Buy rating on the ...

Jefferies analyst Tycho Peterson raised the firm’s price target on Exact Sciences (EXAS) to $85 from $84 and keeps a Buy rating on the ...

Exact Sciences Corporation EXAS reported a net loss of 21 cents in third-quarter 2024 compared with break-even earnings in ...

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based ...

Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.

Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment ...

On Friday, Exact Sciences Corp (EXAS) stock saw a decline, ending the day at $69.11 which represents a decrease of $-1.15 or -1.64% from the prior close of $70.26. The stock opened at $70.2 and ...

Exact Sciences Corp showcases robust revenue growth amidst operational challenges. Innovative cancer screening and diagnostic tests position the company at the forefront of the healthcare industry.